Compare · MRNA vs RXRX
MRNA vs RXRX
Side-by-side comparison of Moderna Inc. (MRNA) and Recursion Pharmaceuticals Inc. (RXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and RXRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $26.59B, about 15.2x RXRX ($1.75B).
- Over the past year, MRNA is up 103.8% and RXRX is down 37.5% - MRNA leads by 141.3 points.
- RXRX has been more active in the news (11 items in the past 4 weeks vs 9 for MRNA).
- MRNA has more recent analyst coverage (25 ratings vs 10 for RXRX).
- Company
- Moderna Inc.
- Recursion Pharmaceuticals Inc.
- Price
- $66.99-1.86%
- $3.30-7.56%
- Market cap
- $26.59B
- $1.75B
- 1M return
- +45.63%
- +8.73%
- 1Y return
- +103.80%
- -37.50%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 9
- 11
- Recent ratings
- 25
- 10
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Latest MRNA
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester
- Moderna Science Day Highlights Expanding Potential of mRNA Platform
- Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
Latest RXRX
- Director Borgeson Blake sold $158,500 worth of shares (40,000 units at $3.96) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 6,218,287 units (SEC Form 4)
- Director Dar Zavain was granted 5,109 shares, increasing direct ownership by 2% to 240,764 units (SEC Form 4)
- Director Li Dean Y was granted 3,747 shares, increasing direct ownership by 0.25% to 1,473,329 units (SEC Form 4)
- A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
- Director Borgeson Blake was granted 88,424 shares, increasing direct ownership by 1% to 6,258,287 units (SEC Form 4)
- Director Hershberg Robert was granted 88,424 shares, increasing direct ownership by 120% to 162,156 units (SEC Form 4)
- Director Michor Franziska was granted 88,424 shares, increasing direct ownership by 70% to 215,477 units (SEC Form 4)
- Director Sun Elaine D was granted 88,424 shares, increasing direct ownership by 186% to 135,981 units (SEC Form 4)
- Director Dar Zavain was granted 88,424 shares, increasing direct ownership by 60% to 235,655 units (SEC Form 4)
- Director Bumpus Namandje was granted 88,424 shares and sold $12,602 worth of shares (3,963 units at $3.18) as part of a pre-agreed trading plan, increasing direct ownership by 196% to 127,632 units (SEC Form 4)